RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.

Jeremie Calais,Wolfgang P. Fendler,Matthias Eiber,Michael Lassmann,Magnus Dahlbom,Rouzbeh Esfandiari,Jeannine Gartmann,Kathleen Nguyen,Pan Thin,Vincent Lok,Ken Herrmann,Johannes Czernin,Ebrahim S. Delpassand

RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.

2019

Jeremie Calais
Wolfgang P. Fendler
Matthias Eiber
Michael Lassmann
Magnus Dahlbom
Rouzbeh Esfandiari
Jeannine Gartmann
Kathleen Nguyen
Pan Thin
Vincent Lok
Ken Herrmann
Johannes Czernin
Ebrahim S. Delpassand

5028Background: This is an investigator-initiated open-label prospective bi-centric single-arm phase 2 clinical trial (NCT03042312) of 177Lu-PSMA-617 radionuclide therapy in patients with progressi...

Keywords:

Oncology
177Lu-PSMA-617
Internal medicine
in patient
Medicine
radionuclide therapy
Phases of clinical research
Castrate-resistant prostate cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations